Abstract 1168P
Background
Lung cancer is the fourth most common cancer, diagnosed in Spain in both sexes with a 5-year survival of 12.7% in men and 17.6% in women. In 2019, the incidence of lung cancer in our country was 29,053 cases.
Methods
We analyzed the clinical characteristics and survival in resected patients with stages I-IIIA included in the TTR.
Results
1,314 p with stage I, II, IIIA, who were operated and had relapsed, were included. The median age was 65 years (range 15-87). 75.3% were men. 98.4% of them were Caucasian. 30% were asymptomatic at the time of diagnosis. The most frequent symptoms being cough (26%), dyspnea (15.4% ) and pain (14.6%). The main histological subtype was adenocarcinoma (62.6%) followed by squamous carcinoma (30%). The surgical margins were R0 in 76% of the cases, R1 and R2 in 6.4% and 2.4% of the cases, respectively. The percentage of local recurrence was 42.7%, to distance 28.1%, and 24% in both. The organs most frequently affected by the relapse were: lung (54%), bones (16.3%), central nervous system (12.3%) and liver (7.7%). The median follow-up was 36.5 months (range 0.1-244.4 months) for all patients and 44.1 months (range 0.9-244.4 months) for patients who had not died. During this follow-up, 733 deaths (55.8%) were registered, 577 of which due to lung cancer. The estimated survival for stage I was 81.7 months (95% CI 68.7-91.1 months), 45.1 months (95% CI 40.4-52.0 months) for stage II and 44.7 months (95% CI 38.5-48.3 months) stage IIIA. With significant differences in survival between stage I and II-IIIA (p <0.001). The estimated overall survival in stage I was 96.3% (95% CI 94.1-97.7%) at 12 months, 88.8% (95% CI 85.5-91.4%) at 24 months and 59.4% (95% CI 54.1-64.4%) at 60 months. In stage II it was 92.3% (95% CI 89.2-94.6%), 76.0% (95% CI 71.3-80.1%) and 40.7% (95% CI 35, 0-46.4%) and in stage IIIA 90.7% (95% CI 87.7-93.1%), 69.7% (95% CI 65.1-73.8%) and 35, 4% (95% CI 30.3-40.5%) respectively.
Conclusions
The stage of the disease is the most important prognostic factor for the disease relapse, with clear differences between completely resected stage I and IIIA. P with stage I tumors have a superior survival, compared to stages II-IIIA, without any differences between them.
Clinical trial identification
NCT02941458.
Editorial acknowledgement
Legal entity responsible for the study
Fundacion GECP.
Funding
Roche, AstraZeneca, Novartis.
Disclosure
All authors have declared no conflicts of interest.